Houston, TX, United States of America

Arumugam Jayakumar

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: The University of Texas System. Active years: 2020.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2020

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Arumugam Jayakumar: Innovator in Pharmaceutical Chemistry

Introduction

Arumugam Jayakumar is a notable inventor based in Houston, Texas. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on caffeic acid derivatives. His research focuses on the potential applications of these compounds in treating serious health conditions, including cancer.

Latest Patents

Arumugam Jayakumar holds a patent for "Caffeic acid derivatives and uses thereof." This patent outlines various caffeic acid derivatives and their pharmaceutical compositions. The compounds described in the patent are intended for use in methods that may aid in the treatment of cancer, showcasing the potential impact of his work on medical science.

Career Highlights

Jayakumar is affiliated with the University of Texas System, where he continues to engage in research and development. His work has garnered attention for its innovative approach to addressing complex health issues through chemical compounds.

Collaborations

Some of his notable coworkers include Waldemar Priebe and Stanislaw Skora. Their collaborative efforts contribute to the advancement of research in the field of pharmaceutical chemistry.

Conclusion

Arumugam Jayakumar's contributions to the field of pharmaceutical chemistry, particularly through his patent on caffeic acid derivatives, highlight his role as an innovator in medical research. His work has the potential to influence cancer treatment and improve patient outcomes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…